We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gala Therapeutics has announced the U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to commence its pivotal clinical trial called RheSolve, which is designed to evaluate the ...
Gala Therapeutics announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOx Bronchial Rheoplasty system.